CLAIM CARD
The evidence base for ACE inhibitors in the context of aging-related cardiometabolic outcomes comprises five studies, predominantly observational in design. Lin 2026 conducted an observational cohort emulating a target trial, examining mean weight change associated with initiation of and adherence to antihypertensive medications, including lisinopril, relative to comparators like amlodipine over a 24-month period in adults. Din 2026 performed a prospective randomized controlled study evaluating sexual function among hypertensive females receiving ramipril 2.5 mg daily for one month. Spiegeleer 2025 focused on older adults in an observational cohort, analyzing the association between statins and gait speed reserve (GSR) while considering concomitant medications, including ACE inhibitors. Azizzadeh 2026 conducted an observational cohort study, the LEAD study, examining the prevalence and determinants of vascular aging in Austrian adults, which included pharmacological treatments for diabetes and hypertension. The single clinical RCT, Zhang 2025, compared nifedipine-GITS and ramipril in Chinese and European patients with hypertension, providing direct evidence on blood pressure reduction.
Evidence grade: exploratory
Contradiction status: none
Publication: 9ab2e887-2e5b-429a-8d89-fd6d7813a028
Provenance: Derivation Web chain
Citation Support
source_1Lin 2026source_2Din 2026source_3Spiegeleer 2025source_4Shen 2025source_5Bene 2025